Zacks Investment Research upgraded shares of Curis Inc. (NASDAQ:CRIS) from a sell rating to a hold rating in a research report report published on Tuesday morning.

According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “

Several other analysts have also recently issued reports on the company. Robert W. Baird reiterated an outperform rating and set a $7.00 target price on shares of Curis in a research report on Wednesday, September 7th. FBR & Co reiterated a buy rating on shares of Curis in a research report on Thursday, September 8th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $4.56.

Curis (NASDAQ:CRIS) opened at 2.74 on Tuesday. Curis has a 1-year low of $1.25 and a 1-year high of $3.18. The stock’s 50 day moving average price is $2.02 and its 200 day moving average price is $1.81. The stock’s market capitalization is $354.75 million.

Curis (NASDAQ:CRIS) last released its earnings results on Thursday, August 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). Curis had a negative return on equity of 65.51% and a negative net margin of 526.72%. The firm earned $1.70 million during the quarter, compared to analysts’ expectations of $2.05 million. During the same quarter last year, the business posted ($0.06) earnings per share. The firm’s revenue was down 19.0% on a year-over-year basis. On average, equities research analysts predict that Curis will post ($0.38) earnings per share for the current fiscal year.

In other Curis news, major shareholder Discovery Technologie Aurigene purchased 10,208,333 shares of the firm’s stock in a transaction that occurred on Wednesday, September 7th. The stock was purchased at an average cost of $2.40 per share, with a total value of $24,499,999.20. Following the purchase, the insider now owns 27,328,464 shares of the company’s stock, valued at $65,588,313.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.09% of the stock is owned by insiders.

Several large investors have recently modified their holdings of CRIS. ProShare Advisors LLC raised its stake in shares of Curis by 1.3% in the second quarter. ProShare Advisors LLC now owns 109,812 shares of the company’s stock worth $171,000 after buying an additional 1,418 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Curis by 27.2% in the second quarter. Rhumbline Advisers now owns 138,986 shares of the company’s stock worth $217,000 after buying an additional 29,751 shares in the last quarter. Teachers Advisors Inc. raised its stake in shares of Curis by 11.5% in the second quarter. Teachers Advisors Inc. now owns 180,776 shares of the company’s stock worth $282,000 after buying an additional 18,634 shares in the last quarter. TFS Capital LLC raised its stake in shares of Curis by 92.4% in the second quarter. TFS Capital LLC now owns 425,243 shares of the company’s stock worth $663,000 after buying an additional 204,278 shares in the last quarter. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of Curis during the second quarter worth about $310,000. 52.36% of the stock is owned by hedge funds and other institutional investors.

Curis Company Profile

Curis, Inc is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.

5 Day Chart for NASDAQ:CRIS

Receive News & Stock Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related stocks with our FREE daily email newsletter.